VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Technical Scanner
RSI, Moving averages & volume momentum signals
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
Minervini — VCPContraction bases in Stage 2 uptrends
Minervini — Trend TemplateFull 8-rule Stage 2 screen
O'Neil — Cup with HandleBase breakouts with RS leadership
O'Neil — CANSLIM LeadersGrowth leaders with RS ≥ 85
Qullamaggie — High Tight FlagsPower plays after a large advance
Qullamaggie — Momentum Leaders1/3/6-month strength leaders
Livermore — Pivotal PointsMulti-touch resistance breakouts
View All Playbooks...
Breakouts
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
Breakouts
WatchlistPricing
Ctrl K
Pricing
GDRX
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsCompareWatchlist
GDRXGoodRx Holdings, Inc.
$3.32$1.2B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksGDRXP/E History

GDRX logoGoodRx Holdings, Inc. (GDRX) P/E Ratio History

Undervalued

Trading at 38.9x vs 5Y avg 842.4x · 20th percentile · Below historical baseline · Data 2020–2026

Current P/E (TTM)
38.9x
-95% vs 5Y avg
5Y Avg P/E
842.4x
Median 67.4x
5Y Percentile
20th
Lower end of range
PEG Ratio
N/A
5-Year P/E Range
38.9x
Min31.8xMedian67.4xMax7722.2x
TTM EPS$0.05
Price$3.32
Earnings Yield2.57%
EPS Growth (1Y)104.1%
EPS Growth (5Y)N/A

Loading P/E history...

P/E Ratio Analysis

As of September 24, 2026, GoodRx Holdings, Inc. (GDRX) trades at a price-to-earnings ratio of 38.9x, with a stock price of $3.32 and trailing twelve-month earnings per share of $0.05.

The current P/E is 95% below its 5-year average of 842.4x. Over the past five years, GDRX's P/E has ranged from a low of 31.8x to a high of 7722.2x, placing the current valuation at the 20th percentile of its historical range.

Compared to the Healthcare sector median P/E of 23.7x, GDRX trades at a 64% premium to its sector peers. The sector includes 225 companies with P/E ratios ranging from 0.0x to 167.0x.

Relative to the broader market, GDRX commands a significant premium over the S&P 500 median P/E of 25.3x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.

For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our GDRX DCF Valuation Calculator →

Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.

GDRX Cross-Benchmark Valuation

How does the current P/E compare to sector peers and the broader market?

vs. Healthcare
38.9vs23.7
+64%
Above Sector
vs. S&P 500
38.9vs25.3
+54%
Above Market
PEG Analysis
N/A
P/E ÷ EPS Growth
Based on 104% EPS growth (1Y)

GDRX P/E vs Peers

Patient Engagement, Intake and Payments peers sorted by market cap

CompanyMarket CapP/E RatioPEG RatioEPS Growth (1Y)
HIMS logoHIMSHims & Hers Health, Inc.
$6B55.7--4%
OPRX logoOPRXOptimizeRx Corp.
$143M28.1-+125%
DOCS logoDOCSDoximity, Inc.
$5B27.10.52Best-12%
PGNY logoPGNYProgyny, Inc.
$2B39.75.93+14%
CVS logoCVSCVS Health Corp.
$110B61.8--62%
MCK logoMCKMcKesson Corporation
$105B22.9Lowest-+49%
CAH logoCAHCardinal Health, Inc.
$52B30.6-+325%Best

Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.

GDRX Historical P/E Data (2020–2026)

Quarterly P/E ratios calculated from closing price and TTM EPS

QuarterPeriod EndPriceTTM EPSP/E Ratiovs Avg
FY2026 Q2-$2.88$0.0467.8x-92%
FY2026 Q1-$1.96$0.0633.5x-96%
FY2025 Q4Dec 31 2025$2.71$0.0931.8x-96%
FY2025 Q3-$4.23$0.0947.4x-94%
FY2025 Q2Jun 30 2025$4.98$0.1242.3x-95%
FY2025 Q1Mar 31 2025$4.41$0.1043.4x-95%
FY2024 Q4-$4.65$0.0767.4x-92%
FY2023 Q3Sep 30 2023$5.63$0.03165.1x-80%
FY2023 Q2Jun 30 2023$5.52$0.03202.9x-76%
FY2020 Q3Sep 30 2020$55.60$0.017722.2x+817%

Average P/E for displayed period: 842.4x

Export Data
Consensus & Technical Research Suite
Open GDRX Terminal

GDRX Chart Terminal

WASM

Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.

Launch Terminal

Live Breakouts Feed

LIVE

High-probability breakout stocks crossing their pivot across 5 pattern engines.

Explore Setups

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

6+ years return with dividends reinvested.

Calculate

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

GDRX — Frequently Asked Questions

Quick answers to the most common questions about buying GDRX stock.

What is GDRX's P/E ratio?

GoodRx Holdings, Inc. (GDRX) trailing twelve-month P/E ratio is 38.9x, based on TTM diluted EPS of $0.05. The 5-year average P/E is 842.4x and the historical range spans 31.8x to 7722.2x.

Is GDRX stock overvalued or undervalued?

GDRX trades at 38.9x P/E, below its 5-year average of 842.4x. At the 20th percentile of its historical range (31.8x–7722.2x), the stock is priced at a discount to its own history.

Is GDRX stock expensive?

No, GDRX is not expensive on a historical basis. The current P/E of 38.9x is below the 5-year average of 842.4x and sits at the 20th percentile of its valuation range.

What is GDRX's historical P/E range?

Over the past 5 years, GDRX's P/E ratio has ranged from 31.8x to 7722.2x, with a median of 67.4x and an average of 842.4x. The current P/E of 38.9x places the stock at the 20th percentile of this range. Full historical data spans 2020–2026.

How does GDRX's P/E compare to the S&P 500?

GDRX trades at 38.9x P/E versus the S&P 500 median of 25.3x. The 54% premium to the market typically reflects higher expected earnings growth or quality.

How does GDRX's valuation compare to Healthcare peers?

GoodRx Holdings, Inc. P/E of 38.9x compares to the Healthcare sector median of 23.7x. The premium reflects expected growth above peers or stronger fundamentals. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.

What is GDRX's PEG ratio?

GDRX PEG ratio is N/A, based on a P/E of 38.9x and EPS growth of 104.1%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.

What is GDRX's earnings yield?

GDRX earnings yield is 2.57%, the inverse of its 38.9x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.

GDRX P/E Ratio History (2020–2026)

Quarterly valuation multiple from closing price and trailing EPS

Current67.8x
Period Avg842.4x
Range31.8x - 7722.2x
Change-99%
10 quartersSep 30, 2020 - Jun 30, 2026